生产企业：VarmX
Recombinant modified human coagulation Factor X protein engineered to be insensitive to Factor Xa inhibitors; bypasses their anticoagulant activity and supports restoration of the coagulation cascade, thereby rapidly restoring blood coagulation in the presence of factor Xa anti-coagulants.
共 1 项相关疾病
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
